首页> 外文期刊>European journal of clinical microbiology and infectious diseases: Official publication of the European Society of Clinical Microbiology >Evaluation of the Accelerate Pheno (TM) system for rapid identification and antimicrobial susceptibility testing of Gram-negative bacteria in bloodstream infections
【24h】

Evaluation of the Accelerate Pheno (TM) system for rapid identification and antimicrobial susceptibility testing of Gram-negative bacteria in bloodstream infections

机译:评价加速酚类(TM)系统进行血流感染革兰阴性细菌的快速鉴定和抗微生物敏感性试验

获取原文
获取原文并翻译 | 示例
       

摘要

Identification and antimicrobial susceptibility testing (AST) are critical steps in the management of bloodstream infections. Our objective was to evaluate the performance of the Accelerate Pheno (TM) System, CE v1.2 software, for identification and AST of Gram-negative pathogens from positive blood culture bottles. A total of 104 bottles positive for Gram-negative bacteria collected from inpatients throughout our institution were randomly selected after Gram staining. The time-to-identification and AST results, and the raw AST results obtained by the Accelerate Pheno (TM) system and routine techniques (MALDI-TOF MS and VITEKA (R) 2, EUCAST guidelines) were compared. Any discrepant AST result was tested by microdilution. The Pheno (TM) significantly improved turn-around times for identification (5.3 versus 23.7 h; p 0.0001) and AST (10.7 versus 35.1 h; p 0.0001). Complete agreement between the Accelerate Pheno (TM) system and the MALDI-TOF MS for identification was observed for 96.2% of samples; it was 99% (98/99) for monomicrobial samples versus 40% (3/5) for polymicrobial ones. The overall categorical agreement for AST was 93.7%; it was notably decreased for beta-lactams (cefepime 84.4%, piperacillin-tazobactam 86.5%, ceftazidime 87.6%) or Pseudomonas aeruginosa (71.9%; with cefepime 33.3%, piperacillin-tazobactam 77.8%, ceftazidime 0%). Analysis of discrepant results found impaired performance of the Accelerate Pheno (TM) system for beta-lactams (except cefepime) in Enterobacteriales (six very major errors) and poor performance in P. aeruginosa. The Accelerate Pheno (TM) system significantly improved the turn-around times for bloodstream infection diagnosis. Nonetheless, improvements in the analysis of polymicrobial samples and in AST algorithms, notably beta-lactam testing in both P. aeruginosa and Enterobacteriales, are required for implementation in routine workflow.
机译:None

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号